Clinical Study of Abdominal Aortic Aneurysm Exclusion (TALENT Abdominal)
NCT ID: NCT00549432
Last Updated: 2009-05-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
75 participants
Study Classification
INTERVENTIONAL
Study Start Date
2002-10-31
Study Completion Date
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of the study is to evaluate the TALENT endoluminal stent-graft system in patients with abdominal aortic aneurysms. The TALENT endoluminal stent-graft system is a flexible, implantable endoluminal vascular device preloaded in a placement system that is used to exclude abdominal aortic aneurysms.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Talent Aortic Cuff Stent Graft System Compassionate Use Registry
NCT00604643
Abdominal Aortic Aneurysms
NO_LONGER_AVAILABLE
Endovascular Repair of Descending Thoracic Aortic Aneurysms
NCT00802984
Aortic Aneurysm, Thoracic
COMPLETED
PHASE4
Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms
NCT00816062
Aortic Aneurysm, Abdominal
COMPLETED
NA
Clinical Study of Thoracic Aortic Aneurysm Exclusion
NCT00549315
Thoracic Aortic Aneurysm
UNKNOWN
NA
Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions
NCT00597870
Thoracic Aortic Aneurysms
Thoracic Transections
Intramural Hematoma
+2 more
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An aneurysm is a localized dilatation of a blood vessel at least 1 1/2 to 2 times the normal vessel diameter. Abdominal aortic aneurysms are relatively common, and have been detected in 1.3% to 2.7% of patients 65 to 80 years of age (Blum, et al, 1996; Collins, Araujo, and Lindsell, 1988; Scott, Ashton, and Kay, 1991). A large proportion (up to 50%) of patients with untreated AAAs experience rupture and exsanguination (Johansen, 1995). Ruptured AAAs are the 13th leading cause of death in the US, accounting for more than 15,000 deaths per year (Cronenwett and Sampson, 1995).
Conventional treatment of abdominal aortic aneurysms is by a surgical procedure involving midline laparotomy, aortic clamping, aortic bypass, and blood loss with associated transfusion. Improvements in surgical techniques and patient care have allowed the mortality rate associated with this procedure to be reduced to approximately 5%, when elective repair is done prior to rupture of the aneurysm. Risks of surgery increase when the patient is considered to be a poor candidate for surgery.
Due to progress made in interventional radiology and endovascular surgery, it is now possible to treat aneurysms without an abdominal surgical procedure, thus potentially further reducing the risks associated with elective repair. This new therapeutic approach consists of transfemoral introduction of a metallic stent coupled with a vascular graft. When the stent device is deployed and expanded within the aneurysmal blood vessel, it creates a new aortic lumen for blood flow, effectively excluding the aneurysm sac from the flow while maintaining perfusion to the lower limbs. This less invasive technique is designed to prevent the need for laparotomy, to reduce the need for blood transfusions, to decrease the use of anesthetics and other drugs, and to speed recovery time.
The objective of this study is to evaluate the safety and effectiveness of the TALENT endoluminal stent-graft system in patients who may be categorized as standard risk, high risk or other indications. Standard risk patients are patients with indications for treatment that are consistent with those for a manufacturer IDE, when there is no active enrollment in the IDE. High risk patients are patients who do not meet the entrance criteria for the manufacturer sponsored IDE as they are at high risk of morbidity and mortality with standard surgical repair. Other indications would be considered patients with indications for treatment outside of those or the manufacturer sponsored IDE.
This study will be performed in both high risk and low risk patients who are considered good candidates for endoluminal repair of abdominal aortic aneurysms. Patients should be heparinized during the implant procedure such that an activated clotting time of 300 seconds is achieved. During implantation of the TALENT endoluminal stent-graft, the pre-implant CT scan and available angiograms are used together with (on-the-table) digital subtraction angiography (DSA), roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The introducer sheath and delivery catheter containing the stent-graft is inserted over a guidewire and advanced into the aorta and above the aneurysm. With the delivery catheter in the correct position, the push rod is held stationary while the outer sheath is slowly withdrawn. The introducer sheath is then withdrawn further until the stent-graft is completely deployed. The balloon may be inflated along the full length of the implanted device to model the springs against the vessel wall and to unravel possible wrinkles in the graft fabric. After deployment of the stent-graft, angiography is performed to verify implant position and to check for the presence of endoleaks.
Subjects will undergo an evaluation of the TALENT endoluminal stent-graft to determine the safety and efficacy of the device as indicated by the adverse event rate, and to determine the risk factors that are most predictive of a successful outcome when used to exclude abdominal aortic aneurysms that require suprarenal fixation in high risk and low risk patients. Follow-up will be completed at 1, 6, 12, 24, 36, 48, and 60 months. Subject evaluation at 1 month will include a complete Physical Examination, Bilateral ABIs, and a Duplex Ultrasound (if not previously completed at time of discharge). Subject evaluation at 6 months will also include a Complete Physical Examination, Bilateral ABIs, Duplex Ultrasound, and Abdominal X-ray (AP, Lateral, 2 Obliques). Subject evaluation at 12, 24, 36, 48, and 60 months will include a Complete Physical Examination, Bilateral ABIs, Abdominal X-ray (AP, Lateral, 2 Obliques), and Spiral CT scan with and without IV Contrast 2.5mm.
Conventional treatment of abdominal aortic aneurysms is by a surgical procedure involving midline laparotomy, aortic clamping, aortic bypass, and blood loss with associated transfusion. Improvements in surgical techniques and patient care have allowed the mortality rate associated with this procedure to be reduced to approximately 5%, when elective repair is done prior to rupture of the aneurysm. Risks of surgery increase when the patient is considered to be a poor candidate for surgery.
Due to progress made in interventional radiology and endovascular surgery, it is now possible to treat aneurysms without an abdominal surgical procedure, thus potentially further reducing the risks associated with elective repair. This new therapeutic approach consists of transfemoral introduction of a metallic stent coupled with a vascular graft. When the stent device is deployed and expanded within the aneurysmal blood vessel, it creates a new aortic lumen for blood flow, effectively excluding the aneurysm sac from the flow while maintaining perfusion to the lower limbs. This less invasive technique is designed to prevent the need for laparotomy, to reduce the need for blood transfusions, to decrease the use of anesthetics and other drugs, and to speed recovery time.
The objective of this study is to evaluate the safety and effectiveness of the TALENT endoluminal stent-graft system in patients who may be categorized as standard risk, high risk or other indications. Standard risk patients are patients with indications for treatment that are consistent with those for a manufacturer IDE, when there is no active enrollment in the IDE. High risk patients are patients who do not meet the entrance criteria for the manufacturer sponsored IDE as they are at high risk of morbidity and mortality with standard surgical repair. Other indications would be considered patients with indications for treatment outside of those or the manufacturer sponsored IDE.
This study will be performed in both high risk and low risk patients who are considered good candidates for endoluminal repair of abdominal aortic aneurysms. Patients should be heparinized during the implant procedure such that an activated clotting time of 300 seconds is achieved. During implantation of the TALENT endoluminal stent-graft, the pre-implant CT scan and available angiograms are used together with (on-the-table) digital subtraction angiography (DSA), roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The introducer sheath and delivery catheter containing the stent-graft is inserted over a guidewire and advanced into the aorta and above the aneurysm. With the delivery catheter in the correct position, the push rod is held stationary while the outer sheath is slowly withdrawn. The introducer sheath is then withdrawn further until the stent-graft is completely deployed. The balloon may be inflated along the full length of the implanted device to model the springs against the vessel wall and to unravel possible wrinkles in the graft fabric. After deployment of the stent-graft, angiography is performed to verify implant position and to check for the presence of endoleaks.
Subjects will undergo an evaluation of the TALENT endoluminal stent-graft to determine the safety and efficacy of the device as indicated by the adverse event rate, and to determine the risk factors that are most predictive of a successful outcome when used to exclude abdominal aortic aneurysms that require suprarenal fixation in high risk and low risk patients. Follow-up will be completed at 1, 6, 12, 24, 36, 48, and 60 months. Subject evaluation at 1 month will include a complete Physical Examination, Bilateral ABIs, and a Duplex Ultrasound (if not previously completed at time of discharge). Subject evaluation at 6 months will also include a Complete Physical Examination, Bilateral ABIs, Duplex Ultrasound, and Abdominal X-ray (AP, Lateral, 2 Obliques). Subject evaluation at 12, 24, 36, 48, and 60 months will include a Complete Physical Examination, Bilateral ABIs, Abdominal X-ray (AP, Lateral, 2 Obliques), and Spiral CT scan with and without IV Contrast 2.5mm.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Abdominal Aortic Aneurysm
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Group Type
EXPERIMENTAL
TALENT Enhanced LPS Endoluminal Stent-Graft System
Intervention Type
DEVICE
roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TALENT Enhanced LPS Endoluminal Stent-Graft System
roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is ≥ 18 years of age.
* Subject has a proximal AAA neck (distance between the top of the aneurysm and the renal arteries) ≥ 5 mm.
* Subject has a proximal aortic neck diameter ≥ 14 mm and ≤ 32 mm.
* Subject has an angle between the suprarenal aorta and the aneurysm ≤ 60°.
* Subject has renal arteries ≥ 9 cm from the aortic neck bifurcation.
* Subject has proximal and distal iliac neck diameters ≥ 8 mm and ≤ 24 mm.
* Subject has a distal iliac neck length ≥ 15 mm.
* Subject has signed the informed consent.
* Subject will be available for follow-up at periodic intervals after the procedure.
* Subject has a proximal AAA neck (distance between the top of the aneurysm and the renal arteries) ≥ 5 mm.
* Subject has a proximal aortic neck diameter ≥ 14 mm and ≤ 32 mm.
* Subject has an angle between the suprarenal aorta and the aneurysm ≤ 60°.
* Subject has renal arteries ≥ 9 cm from the aortic neck bifurcation.
* Subject has proximal and distal iliac neck diameters ≥ 8 mm and ≤ 24 mm.
* Subject has a distal iliac neck length ≥ 15 mm.
* Subject has signed the informed consent.
* Subject will be available for follow-up at periodic intervals after the procedure.
Exclusion Criteria
* Subject has a document patent inferior mesenteric artery and an occluded or stenotic celiac and superior mesenteric artery.
* Subject has a lesion that cannot be crossed with a guide wire.
* Subject whose arterial access site cannot accommodate the delivery catheter.
* Subject has no distal vascular bed.
* Subject has systemic infection, or is suspected of having systemic infection.
* Subject has an untreatable bleeding diathesis.
* Subject is not available or is not willing to come back for periodic follow-up (surveillance) after the procedure.
* Subject has a lesion that cannot be crossed with a guide wire.
* Subject whose arterial access site cannot accommodate the delivery catheter.
* Subject has no distal vascular bed.
* Subject has systemic infection, or is suspected of having systemic infection.
* Subject has an untreatable bleeding diathesis.
* Subject is not available or is not willing to come back for periodic follow-up (surveillance) after the procedure.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arizona Heart Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arizona Heart Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward B Diethrich, M.D.
Role: PRINCIPAL_INVESTIGATOR
Arizona Heart Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Heart Institute
Phoenix, Arizona, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Becker GJ, Benenati JF, Zemel G, Sallee DS, Suarez CA, Roeren TK, Katzen BT. Percutaneous placement of a balloon-expandable intraluminal graft for life-threatening subclavian arterial hemorrhage. J Vasc Interv Radiol. 1991 May;2(2):225-9. doi: 10.1016/s1051-0443(91)72286-0.
Reference Type
BACKGROUND
Bickerstaff LK, Hollier LH, Van Peenen HJ, Melton LJ 3rd, Pairolero PC, Cherry KJ. Abdominal aortic aneurysms: the changing natural history. J Vasc Surg. 1984 Jan;1(1):6-12.
Reference Type
BACKGROUND
Blum U, Langer M, Spillner G, Mialhe C, Beyersdorf F, Buitrago-Tellez C, Voshage G, Duber C, Schlosser V, Cragg AH. Abdominal aortic aneurysms: preliminary technical and clinical results with transfemoral placement of endovascular self-expanding stent-grafts. Radiology. 1996 Jan;198(1):25-31. doi: 10.1148/radiology.198.1.8539389.
Reference Type
BACKGROUND
Pathology of nonspecific abdominal aortic aneurysm disease. In Current Therapy in Vascular Surgery, 2nd edition, CB Ernst and JC Stanley, eds. B.C. Decker, Philadelphia, PA.
Reference Type
BACKGROUND
Collin J, Araujo L, Walton J, Lindsell D. Oxford screening programme for abdominal aortic aneurysm in men aged 65 to 74 years. Lancet. 1988 Sep 10;2(8611):613-5. doi: 10.1016/s0140-6736(88)90649-6.
Reference Type
BACKGROUND
Cronenwett JL and LN Samspon. 1995. Aneurysms of the abdominal aorta and iliac arteris. In Current Diagnosis and Treatment in Vascular Surgery, 1st edition, RH Dean, JST Yao and DC Brewster, eds. Appleton and Lange, Norwalk, CT. pp 220-238.
Reference Type
BACKGROUND
Dake MD, Miller DC, Semba CP, Mitchell RS, Walker PJ, Liddell RP. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms. N Engl J Med. 1994 Dec 29;331(26):1729-34. doi: 10.1056/NEJM199412293312601.
Reference Type
BACKGROUND
DUBOST C, ALLARY M, OECONOMOS N. Resection of an aneurysm of the abdominal aorta: reestablishment of the continuity by a preserved human arterial graft, with result after five months. AMA Arch Surg. 1952 Mar;64(3):405-8. No abstract available.
Reference Type
BACKGROUND
Geroulakos G, Nicolaides A. Infrarenal abdominal aortic aneurysms less than five centimetres in diameter: the surgeon's dilemma. Eur J Vasc Surg. 1992 Nov;6(6):616-22. doi: 10.1016/s0950-821x(05)80838-2.
Reference Type
BACKGROUND
Gloviczki P. Ruptured abdominal aortic aneurysms. In Vascular Surgery, 4th edition, Rutherford, RB, ed. Saunders, Philadelphia, PA, chapter 76.
Reference Type
BACKGROUND
Hallett JW Jr, Bower TC, Cherry KJ, Gloviczki P, Joyce JW, Pairolero PC. Selection and preparation of high-risk patients for repair of abdominal aortic aneurysms. Mayo Clin Proc. 1994 Aug;69(8):763-8. doi: 10.1016/s0025-6196(12)61096-9.
Reference Type
BACKGROUND
Ingoldby CJ, Wujanto R, Mitchell JE. Impact of vascular surgery on community mortality from ruptured aortic aneurysms. Br J Surg. 1986 Jul;73(7):551-3. doi: 10.1002/bjs.1800730711.
Reference Type
BACKGROUND
Johansson G, Swedenborg J. Ruptured abdominal aortic aneurysms: a study of incidence and mortality. Br J Surg. 1986 Feb;73(2):101-3. doi: 10.1002/bjs.1800730205.
Reference Type
BACKGROUND
Johansen K. Ruptured abdominal aortic aneurysm: how should recent outcome studies impact current practices? Semin Vasc Surg. 1995 Jun;8(2):163-7. No abstract available.
Reference Type
BACKGROUND
Johnston KW. Nonruptured abdominal aortic aneurysm: six-year follow-up results from the multicenter prospective Canadian aneurysm study. Canadian Society for Vascular Surgery Aneurysm Study Group. J Vasc Surg. 1994 Aug;20(2):163-70. doi: 10.1016/0741-5214(94)90002-7.
Reference Type
BACKGROUND
Lee JT, Lee J, Aziz I, Donayre CE, Walot I, Kopchok GE, Heilbron M Jr, Lippmann M, White RA. Stent-graft migration following endovascular repair of aneurysms with large proximal necks: anatomical risk factors and long-term sequelae. J Endovasc Ther. 2002 Oct;9(5):652-64. doi: 10.1177/152660280200900517.
Reference Type
BACKGROUND
Melton LJ 3rd, Bickerstaff LK, Hollier LH, Van Peenen HJ, Lie JT, Pairolero PC, Cherry KJ, O'Fallon WM. Changing incidence of abdominal aortic aneurysms: a population-based study. Am J Epidemiol. 1984 Sep;120(3):379-86. doi: 10.1093/oxfordjournals.aje.a113902.
Reference Type
BACKGROUND
Nehler MR, Taylor LM Jr, Moneta GL, Porter JM. Indications for operation for infrarenal abdominal aortic aneurysms: current guidelines. Semin Vasc Surg. 1995 Jun;8(2):108-14. No abstract available.
Reference Type
BACKGROUND
Nevitt MP, Ballard DJ, Hallett JW Jr. Prognosis of abdominal aortic aneurysms. A population-based study. N Engl J Med. 1989 Oct 12;321(15):1009-14. doi: 10.1056/NEJM198910123211504.
Reference Type
BACKGROUND
O'Donnell TF, Darling RC, Linton RR. Is 80 years too old for aneurysmectomy? Arch Surg. 1976 Nov;111(11):1250-7. doi: 10.1001/archsurg.1976.01360290084012.
Reference Type
BACKGROUND
O'Hara PJ, Hertzer NR, Krajewski LP, Tan M, Xiong X, Beven EG. Ten-year experience with abdominal aortic aneurysm repair in octogenarians: early results and late outcome. J Vasc Surg. 1995 May;21(5):830-7; discussion 837-8. doi: 10.1016/s0741-5214(05)80015-1.
Reference Type
BACKGROUND
Pairolero PC. Repair of abdominal aortic aneurysms in high-risk patients. Surg Clin North Am. 1989 Aug;69(4):755-63. doi: 10.1016/s0039-6109(16)44882-6.
Reference Type
BACKGROUND
Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg. 1991 Nov;5(6):491-9. doi: 10.1007/BF02015271.
Reference Type
BACKGROUND
Perler BA. 1995. Natural history of abdominal aortic aneurysm. A clinical presentation. Seventh Annual International Symposium on Vascular Diagnosis and Intervention. pp. 173-175.
Reference Type
BACKGROUND
Rose WM 3rd, Ernst CB. Abdominal aortic aneurysm. Compr Ther. 1995 Jul;21(7):339-43. No abstract available.
Reference Type
BACKGROUND
Scott RA, Ashton HA, Kay DN. Abdominal aortic aneurysm in 4237 screened patients: prevalence, development and management over 6 years. Br J Surg. 1991 Sep;78(9):1122-5. doi: 10.1002/bjs.1800780929.
Reference Type
BACKGROUND
Veith FJ, Abbott WM, Yao JS, Goldstone J, White RA, Abel D, Dake MD, Ernest CB, Fogarty TJ, Johnston KW, et al. Guidelines for development and use of transluminally placed endovascular prosthetic grafts in the arterial system. Endovascular Graft Committee. J Vasc Surg. 1995 Apr;21(4):670-85. doi: 10.1016/s0741-5214(95)70198-2. No abstract available.
Reference Type
BACKGROUND
Zarins CK, Harris EJ Jr. Operative repair for aortic aneurysms: the gold standard. J Endovasc Surg. 1997 Aug;4(3):232-41. doi: 10.1583/1074-6218(1997)0042.0.CO;2.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
G020149
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Post-Approval Clinical Study of the Talent Thoracic Stent Graft to Treat Thoracic Aortic Aneurysms (THRIVE)
NCT00805948
TERMINATED
NA
VALOR: The Talent Thoracic Stent Graft System Clinical Study
NCT00604799
COMPLETED
PHASE2/PHASE3
Thoracoabdominal Artery Stent Graft System Exploratory Study
NCT06710938
RECRUITING
NA
Aorto-iliac Occlusion Treatment With ShorT Unibody aorTic Endograft - ASTUTE Study
NCT05614856
SUSPENDED
Talent Converter Post-Approval Study
NCT01129609
TERMINATED
Real-world Study on Fenestrated Stent for Thoracic Aortic Dissection
NCT07268755
ACTIVE_NOT_RECRUITING
The Study to Compare the Cordis SMART™ Stent System With the Bard® Luminexx™ Stent
NCT00235131
COMPLETED
PHASE4
Clinical Study of Thoracic Excluder Endoprosthesis to Treat Descending Thoracic Aortic Diseases
NCT00546312
UNKNOWN
NA
Transcatheter Leak Closure With Detachable Coils Following Incomplete Left Atrial Appendage Closure Procedures
NCT03503253
UNKNOWN
NA
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
NCT01524211
RECRUITING
NA
Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System
NCT03687489
UNKNOWN
NA
Safety and Effectiveness of Surgeon-Modified Stent Grafts forTreatment of Complex Aortic Aneurysms
NCT05531084
NOT_YET_RECRUITING
NA
A Real-World Study on Distal Aortic Remodeling for Stanford Type B Aortic Dissection With Fabulous Thoracic Aortic Stent System
NCT05883592
UNKNOWN
Safety and Efficacy Study of Fabulous Stent Graft System for Stanford B Aortic Dissection
NCT04918212
COMPLETED
NA
Expanding Patient Applicability With Polymer Sealing Ovation Alto Stent Graft Investigational Device Exemption (IDE) Study
NCT02949297
COMPLETED
NA
RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
NCT02818972
ACTIVE_NOT_RECRUITING
NA
Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
NCT01526811
COMPLETED
Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System
NCT00705718
COMPLETED
NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
NCT01874197
RECRUITING
NA
PRESERVE-Zenith® Iliac Branch System Clinical Study
NCT01208415
COMPLETED
NA
the Aorta Arch Stent Graft System Combined With the Endovascular Needle System in Situ Fenestration
NCT05126446
ACTIVE_NOT_RECRUITING
NA
A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients
NCT03344653
COMPLETED
NA
A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.
NCT00597142
COMPLETED
PHASE4
Over and Under/Aneugraft Pericardium Covered Stent Long Term Follow up Registry
NCT01307553
UNKNOWN
PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation
NCT02475798
NO_LONGER_AVAILABLE